Maladie de Chagas : Questions médicales fréquentes
Nom anglais: Chagas Disease
Descriptor UI:D014355
Tree Number:C01.920.625
Termes MeSH sélectionnés :
Platelet Glycoprotein GPIIb-IIIa Complex
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Maladie de Chagas : Questions médicales les plus fréquentes",
"headline": "Maladie de Chagas : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Maladie de Chagas : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-25",
"dateModified": "2025-03-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Maladie de Chagas"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Maladies vectorielles",
"url": "https://questionsmedicales.fr/mesh/D000079426",
"about": {
"@type": "MedicalCondition",
"name": "Maladies vectorielles",
"code": {
"@type": "MedicalCode",
"code": "D000079426",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C01.920"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Maladie de Chagas",
"alternateName": "Chagas Disease",
"code": {
"@type": "MedicalCode",
"code": "D014355",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Israel Molina",
"url": "https://questionsmedicales.fr/author/Israel%20Molina",
"affiliation": {
"@type": "Organization",
"name": "Tropical Medicine Unit, Department of Infectious Diseases, Vall d'Hebron University Hospital, PROSICS Barcelona, Barcelona, Spain; Instituto René Rachou-FIOCRUZ Minas, Chagas Disease Research Group, Belo Horizonte, MG, Brazil."
}
},
{
"@type": "Person",
"name": "Eva H Clark",
"url": "https://questionsmedicales.fr/author/Eva%20H%20Clark",
"affiliation": {
"@type": "Organization",
"name": "Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA."
}
},
{
"@type": "Person",
"name": "Caryn Bern",
"url": "https://questionsmedicales.fr/author/Caryn%20Bern",
"affiliation": {
"@type": "Organization",
"name": "Department of Epidemiology and Biostatistics, University of California San Francisco School of Medicine, San Francisco, California, USA."
}
},
{
"@type": "Person",
"name": "Carlos A Morillo",
"url": "https://questionsmedicales.fr/author/Carlos%20A%20Morillo",
"affiliation": {
"@type": "Organization",
"name": "Division of Cardiology, Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, Foothills Medical Centre, Room C823, 1403 29th Street Northwest, Calgary, Alberta T2N 2T9, Canada. Electronic address: carlos.morillo@ucalgary.ca."
}
},
{
"@type": "Person",
"name": "Susan P Montgomery",
"url": "https://questionsmedicales.fr/author/Susan%20P%20Montgomery",
"affiliation": {
"@type": "Organization",
"name": "Parasitic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia (S.P.M.)."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Repeated platelet activation and the potential of previously activated platelets to contribute to thrombus formation.",
"datePublished": "2023-01-14",
"url": "https://questionsmedicales.fr/article/36754678",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jtha.2023.01.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "Management of Abdominal Aortic Aneurysm Surgery in Glanzmann's Thrombasthenia Patients with Anti-GPIIb-IIIa Antibodies: A Case Report.",
"datePublished": "2024-09-30",
"url": "https://questionsmedicales.fr/article/39407899",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/jcm13195839"
}
},
{
"@type": "ScholarlyArticle",
"name": "Increased platelet activation and lower platelet-monocyte aggregates in COVID-19 patients with severe pneumonia.",
"datePublished": "2023-03-08",
"url": "https://questionsmedicales.fr/article/36888618",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0282785"
}
},
{
"@type": "ScholarlyArticle",
"name": "Stoichiometry and architecture of the platelet membrane complex glycoprotein Ib-IX-V.",
"datePublished": "2023-03-22",
"url": "https://questionsmedicales.fr/article/36942505",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1515/hsz-2022-0227"
}
},
{
"@type": "ScholarlyArticle",
"name": "SHIP1 Controls Internal Platelet Contraction and α",
"datePublished": "2023-01-04",
"url": "https://questionsmedicales.fr/article/36674478",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms24020958"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Infection",
"item": "https://questionsmedicales.fr/mesh/D007239"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies vectorielles",
"item": "https://questionsmedicales.fr/mesh/D000079426"
},
{
"@type": "ListItem",
"position": 4,
"name": "Maladie de Chagas",
"item": "https://questionsmedicales.fr/mesh/D014355"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Maladie de Chagas - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Maladie de Chagas",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Maladie de Chagas",
"description": "Comment diagnostique-t-on la maladie de Chagas ?\nQuels examens sont utilisés pour le diagnostic ?\nPeut-on diagnostiquer la maladie par biopsie ?\nQuels sont les signes cliniques au diagnostic ?\nLa maladie de Chagas est-elle toujours symptomatique ?",
"url": "https://questionsmedicales.fr/mesh/D014355?mesh_terms=Platelet+Glycoprotein+GPIIb-IIIa+Complex&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Maladie de Chagas",
"description": "Quels sont les symptômes aigus de la maladie de Chagas ?\nQuels symptômes chroniques peuvent apparaître ?\nY a-t-il des symptômes cutanés associés ?\nComment se manifeste l'œdème de l'œil ?\nLes symptômes varient-ils selon les régions ?",
"url": "https://questionsmedicales.fr/mesh/D014355?mesh_terms=Platelet+Glycoprotein+GPIIb-IIIa+Complex&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Maladie de Chagas",
"description": "Comment prévenir la maladie de Chagas ?\nLes moustiquaires sont-elles efficaces ?\nL'éducation sanitaire joue-t-elle un rôle ?\nLes tests de dépistage sont-ils importants ?\nPeut-on prévenir la transmission par voie orale ?",
"url": "https://questionsmedicales.fr/mesh/D014355?mesh_terms=Platelet+Glycoprotein+GPIIb-IIIa+Complex&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Maladie de Chagas",
"description": "Quel est le traitement principal de la maladie de Chagas ?\nLe traitement est-il efficace à tous les stades ?\nY a-t-il des effets secondaires au traitement ?\nDes traitements alternatifs existent-ils ?\nLe traitement prévient-il les complications ?",
"url": "https://questionsmedicales.fr/mesh/D014355?mesh_terms=Platelet+Glycoprotein+GPIIb-IIIa+Complex&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Maladie de Chagas",
"description": "Quelles sont les complications cardiaques possibles ?\nLa maladie peut-elle affecter le système digestif ?\nY a-t-il des risques de décès liés à la maladie ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D014355?mesh_terms=Platelet+Glycoprotein+GPIIb-IIIa+Complex&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Maladie de Chagas",
"description": "Quels sont les principaux facteurs de risque ?\nLes voyages dans certaines régions augmentent-ils le risque ?\nLes conditions de vie influencent-elles le risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nLes personnes immunodéprimées sont-elles plus à risque ?",
"url": "https://questionsmedicales.fr/mesh/D014355?mesh_terms=Platelet+Glycoprotein+GPIIb-IIIa+Complex&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on la maladie de Chagas ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sérologiques pour détecter les anticorps anti-T. cruzi."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme l'ELISA, l'immunofluorescence et la PCR sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer la maladie par biopsie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une biopsie de tissu peut révéler la présence du parasite dans certains cas."
}
},
{
"@type": "Question",
"name": "Quels sont les signes cliniques au diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes peuvent inclure des œdèmes, des éruptions cutanées et des symptômes cardiaques."
}
},
{
"@type": "Question",
"name": "La maladie de Chagas est-elle toujours symptomatique ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elle peut être asymptomatique pendant des années avant d'entraîner des complications."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes aigus de la maladie de Chagas ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes aigus incluent fièvre, fatigue, et gonflement au site de la piqûre."
}
},
{
"@type": "Question",
"name": "Quels symptômes chroniques peuvent apparaître ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes chroniques incluent des problèmes cardiaques et digestifs, comme l'arythmie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des éruptions cutanées et des lésions peuvent se développer, surtout au stade aigu."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'œdème de l'œil ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'œdème de l'œil, ou signe de Romaña, se manifeste par un gonflement autour de l'œil."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les régions ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la souche du parasite et de l'hôte."
}
},
{
"@type": "Question",
"name": "Comment prévenir la maladie de Chagas ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut l'amélioration des conditions de logement et l'utilisation d'insecticides."
}
},
{
"@type": "Question",
"name": "Les moustiquaires sont-elles efficaces ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les moustiquaires peuvent réduire le contact avec les insectes vecteurs de la maladie."
}
},
{
"@type": "Question",
"name": "L'éducation sanitaire joue-t-elle un rôle ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur les risques et les méthodes de prévention est cruciale pour réduire l'incidence."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage des donneurs de sang et des femmes enceintes est essentiel pour prévenir la transmission."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la transmission par voie orale ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter la consommation d'aliments contaminés peut prévenir la transmission orale de la maladie."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal de la maladie de Chagas ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est l'utilisation de médicaments antiparasitaires comme le benznidazole."
}
},
{
"@type": "Question",
"name": "Le traitement est-il efficace à tous les stades ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement est plus efficace au stade aigu; son efficacité diminue au stade chronique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires au traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des éruptions cutanées et des troubles gastro-intestinaux peuvent survenir."
}
},
{
"@type": "Question",
"name": "Des traitements alternatifs existent-ils ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements alternatifs sont en cours d'étude, mais le benznidazole reste le standard."
}
},
{
"@type": "Question",
"name": "Le traitement prévient-il les complications ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement précoce peut réduire le risque de complications à long terme, comme les problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications cardiaques possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications cardiaques incluent l'insuffisance cardiaque, les arythmies et la cardiomyopathie."
}
},
{
"@type": "Question",
"name": "La maladie peut-elle affecter le système digestif ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications digestives comme l'agrandissement de l'œsophage ou du côlon peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de décès liés à la maladie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications graves peuvent entraîner la mort, surtout si non traitées."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais beaucoup sont irréversibles sans traitement précoce."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent gravement affecter la qualité de vie, limitant les activités quotidiennes."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent la pauvreté, le manque d'accès à des logements sains et l'exposition aux insectes vecteurs."
}
},
{
"@type": "Question",
"name": "Les voyages dans certaines régions augmentent-ils le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones endémiques augmente le risque d'exposition au parasite."
}
},
{
"@type": "Question",
"name": "Les conditions de vie influencent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, vivre dans des habitations en terre ou en bois augmente le risque d'infestation par les triatomes."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avoir des antécédents familiaux de la maladie peut augmenter le risque d'infection."
}
},
{
"@type": "Question",
"name": "Les personnes immunodéprimées sont-elles plus à risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunodéprimées peuvent être plus susceptibles de développer des formes graves de la maladie."
}
}
]
}
]
}
Especially in disease conditions, platelets can encounter activating agents in circulation....
To investigate the extent to which previously activated platelets can be reactivated and whether in-and reactivation applies to different aspects of platelet activation and thrombus formation....
Short-and long-term effects of glycoprotein VI (GPVI) and G protein-coupled receptor (GPCR) stimulation on platelet activation and aggregation potential were compared via flow cytometry and plate-base...
After 30 minutes of stimulation with thrombin receptor activator peptide 6 (TRAP6) or adenosine diphosphate (ADP), platelets secondarily decreased in PAC-1 binding and were less able to aggregate. The...
This work emphasizes that prior platelet activation can be reversed, whereafter platelets can be reactivated through a different receptor. Reversed, previously activated platelets can contribute to th...
Glanzmann's thrombasthenia (GT) is a rare autosomal recessive disorder of platelet function. The frequent occurrence of alloimmunization due to repeated platelet transfusions is the major complication...
The increased procoagulant platelets and platelet activation are associated with thrombosis in COVID-19. In this study, we investigated platelet activation in COVID-19 patients and their association w...
COVID-19 patients were classified into three severity groups: no pneumonia, mild-to-moderate pneumonia, and severe pneumonia. The expression of P-selectin and activated glycoprotein (aGP) IIb/IIIa on ...
P-selectin expression, platelet-neutrophil, platelet-lymphocyte, and platelet-monocyte aggregates were higher in COVID-19 patients than in uninfected control individuals. In contrast, aGPIIb/IIIa expr...
COVID-19 patients have higher platelet-leukocyte aggregates and P-selectin expression than controls, indicating increased platelet activation. Compared within patient groups, platelet-monocyte aggrega...
Glycoprotein (GP) Ib-IX-V is the second most abundant platelet receptor for thrombin and other ligands crucial for hemostasis and thrombosis. Its activity is involved in platelet adhesion to vascular ...
Monocyte-platelet aggregates (MPAs) represent the crossroads between thrombosis and inflammation, and targeting this axis may suppress thromboinflammation. While antiplatelet therapy (APT) reduces pla...
To analyze the effect of platelets on monocyte activation and APT on MPA and platelet-induced monocyte activation....
Agonist-stimulated whole blood was incubated in the presence of P-selectin, PSGL1, PAR1, P2Y...
Consistent with a proinflammatory platelet effector role, MPAs were increased in patients with COVID-19. RNA-Seq revealed a thromboinflammatory monocyte transcriptome upon incubation with platelets. M...
Integrins are heterodimeric transmembrane receptors composed of α and β chains, with an N-terminal extracellular domain forming a globular head corresponding to the ligand binding site. Integrins regu...
Deep vein thrombosis (DVT) is a prevalent cardiovascular condition. Endothelial-derived extracellular vesicles (EVs) may play a crucial role in platelet-dependent DVT development via platelet activati...
The interaction between protein disulfide isomerase (PDI) and glucose-regulated protein 94 (GRP94) was founded by molecular docking. Inferior vena cava stasis-induced mice received PDI and GRP94 inhib...
In a DVT mouse model, platelets enhance venous thrombus formation in a coagulation-independent manner, instead, platelet activation and the length of the thrombus are related to PDI and GRP94 activity...
Endothelial-derived EVs carrying PDI induce DVT via interplay with GRP94 and GPIIb/IIIa in platelets. These findings emphasize the significance of platelets in DVT formation, and PDI may be a suitable...
Coumarin was first discovered in Tonka bean and then widely in other plants. Coumarin has an anticoagulant effect, and its derivative, warfarin, is a vitamin K analogue that inhibits the synthesis of ...
Platelet endothelial aggregation receptor 1 (PEAR1) is a single-transmembrane orphan receptor primarily expressed on platelets and endothelial cells. Genetic variants of PEAR1 have repeatedly and inde...
We have identified sulfated fucoidans and their mimetics as ligands for PEAR1 and proposed that its endogenous ligand is a sulfated proteoglycan. The aim of this study was to test this hypothesis....
A heparin proteoglycan-mimetic (HPGM) was created by linking unfractionated heparin (UFH) to albumin. The ability of the HPGM, UFH and selectively desulfated heparins to stimulate platelet aggregation...
We show that HPGM, heparin conjugated to an albumin protein core, stimulates aggregation and phosphorylation of PEAR1 in washed platelets. Platelet aggregation was abolished by an anti-PEAR1 nanobody,...
Our findings reveal that PEAR1 is a receptor for heparin and HPGM and that PI3Kβ is a key signaling molecule downstream of PEAR1 in platelets. These findings may have important implications for our un...